Evaluation of the efficacy, safety, and pharmacokinetics of nanodispersible cannabidiol oral solution (150mg/ml) versus placebo in mild to moderate anxiety subjects: A double blind multicenter randomized clinical trial

Artigo Acesso aberto Revisado por pares

Evaluation of the efficacy, safety, and pharmacokinetics of nanodispersible cannabidiol oral solution (150mg/ml) versus placebo in mild to moderate anxiety subjects: A double blind multicenter randomized clinical trial

2024; Elsevier BV; Volume: 97; Linguagem: Inglês

10.1016/j.ajp.2024.104073

ISSN

1876-2026

Autores

Prasad Rao Gundugurti, Nagaraju Banda, Siva Sankara Rao Yadlapalli, Arjun Narala, Ramyasree Thatikonda, Chandrashekhar Kocherlakota, Kumar S.D. Kothapalli,

Tópico(s)

Psychedelics and Drug Studies

Resumo

Anxiety disorders, an increasingly prevalent global mental health illness, affected approximately 301 million individuals worldwide in 2019. There is an unmet need for the treatment of anxiety disorders, as current therapies are associated with limited response rates, residual symptoms, and adverse effects.

Ver no editor

Altmetric

PlumX

Entrar

Lembrar minha senha

Receber meu e-mail de confirmação

Evaluation of the efficacy, safety, and pharmacokinetics of nanodispersible cannabidiol oral solution (150mg/ml) versus placebo in mild to moderate anxiety subjects: A double blind multicenter randomized clinical trial